Effective prognostic factors such as NSE should be used to classify patients with ALL, and treatments such as hematopoietic stem cell transplantation and more aggressive chemotherapies should be administered to patients with unfavorable prognoses. The gene discussed is ENO2; the disease is acute lymphoblastic leukemia.